Response to Tyrosine Kinase Inhibitors in Myeloproliferative Neoplasia with 8p11 Translocation and CEP110-FGFR1 Rearrangement.

Wehrli, Marc; Oppliger Leibundgut, Elisabeth; Gattiker, Heinrich H; Manz, Markus G; Müller, Antonia M S; Goede, Jeroen S (2017). Response to Tyrosine Kinase Inhibitors in Myeloproliferative Neoplasia with 8p11 Translocation and CEP110-FGFR1 Rearrangement. The oncologist, 22(4), pp. 480-483. AlphaMed Press 10.1634/theoncologist.2016-0354

Text Wehrli M. et al. Response to Tyrosine Kinase Inhibitors in Myeloproliferative Neoplasie with 8p11 Translokation and CWP110-FGFR1 Rearrangement.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (193kB)

This brief communication reports on a patient with an exceedingly rare "8p11 (eight-p-eleven) myeloproliferative syndrome" (EMS) with CEP110-FGFR1 rearrangement who responded to treatment with the multi-tyrosine kinase inhibitor (TKI) dasatinib. Dasatinib improved quality of life substantially by increasing blood counts and reducing the need for transfusions. This report demonstrates that the second-generation TKI may provide a therapeutic option for elderly and frail EMS patients who cannot be offered aggressive therapy, including allogeneic hematopoietic cell transplantation. The Oncologist 2017;22:480-483.

Interest & Impact

Downloads

1 since deposited on 15 May 2018
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item